Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00858156 · ClinicalTrials.gov registry record · Phase 1
BG9928 in Subjects With Hepatic Impairment
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00858156 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 23 participants.
The verdict
NCT00858156, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the effect of hepatic function on the pharmacokinetics of a single oral dose of BG9928 in subjects with mild and moderate hepatic impairment and in subjects with normal hepatic function.
Interventions
- DRUG BG9928
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00858156
The ClinicalTrials.gov registry entry for NCT00858156 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BG9928 is the first listed.
NCT00858156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00858156 about?
NCT00858156 is a clinical study titled "BG9928 in Subjects With Hepatic Impairment". The primary objective of the study is to evaluate the effect of hepatic function on the pharmacokinetics of a single oral dose of BG9928 in subjects with mild and moderate hepatic impairment and in subjects with normal hepatic function.
What is the current status of trial NCT00858156?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2009-04. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00858156?
The interventions under investigation include: BG9928 (DRUG).
Who is sponsoring clinical trial NCT00858156?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.